



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 40923-0080US4

Applicant(s): GOLDENBERG et al.

Confirmation No.: 3453

Appl. No.: 09/590,284

Examiner: I.I. Ouspenski

Filing Date: June 9, 2000

Art Unit: 1644

Title: IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING
ANTIBODIES WHICH TARGET B-CELLS

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

FILING FEE


This submission is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR § 1.114, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: January 6, 2006

HELLER EHRMAN L.L.P
1717 Rhode Island Ave., N.W.
Washington, DC 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

By  _____

Paul M. Booth
Attorney for Applicant
Registration No. 40,244

Customer No. 26633

JAN 06 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

09/590.284

Filing Date

June 9, 2000

First Named Inventor

David M. GOLDENBERG et al.

Group Art Unit

1644

Examiner Name

I.I. Ouspenski

Attorney Docket Number

40923-0080US4

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.